For readers interested in bispecific antibodies as cancer therapies, here's a review rdcu.be/eOONr www.nature.com/articles/s41...

Innovative antibody therapeutic development in China compared with the USA and Europe nature.com/articles/d41... Data indicate that China’s focus on policy-driven innovation is enabling companies based there to surpass those in the USA and Europe in ADC and bispecific development

Cancer cell therapies: global clinical trial trends and emerging directions www.nature.com/articles/d41... This new article byanalyses trends across trial phases, indications, modalities, cell sources and targets to map the current trajectory of the field

For readers interested in the development of drugs for fibrotic diseases such as idiopathic pulmonary fibrosis, here's a review discussing the underlying biology and how to address the translational research challenges rdcu.be/eOpGH www.nature.com/articles/s41...

FDA approves PDE4 inhibitor for idiopathic pulmonary fibrosis www.nature.com/articles/d41... Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade

Induced proximity-based therapeutic modalities nature.com/articles/s41... rdcu.be/eOfBH This new Review by @dannomura.bsky.social et al. discusses the rapidly expanding landscape of therapeutic approaches based on inducing proximity between proteins, including targeted protein degraders and more

For readers interested in new drugs for chronic obstructive pulmonary disease, affecting proteins such as IL-33 and TSLP that are targeted by the bispecific involved in Roche's $1 billion deal with Qyuns Therapeutics, here's a review rdcu.be/eN4SK www.nature.com/articles/s41...

Roche turns to China's Qyuns for preclinical respiratory asset in over $1B deal $RHHBY firstwordpharma.com/story/6511061

Our November issue is live! Read more about drugs for cancer cachexia, RNA chemistry and therapeutics, targeting the Hippo pathway in cancer, the changing landscape of medicinal chemistry optimization and more here www.nature.com/nrd/volumes/...

For readers interested in new drugs for chronic obstructive pulmonary disease, here's a comprehensive review rdcu.be/eNiYv www.nature.com/articles/s41...

In its second pipeline-expanding deal in the space of 24 hours, #GSK has licensed rights to a drug for chronic obstructive pulmonary disease (#COPD) from US biotech #Empirico for $85 million upfront. pharmaphorum.com/news/gsk-str...

For readers interested in the potential to target particular protein isoforms as a way to achieve greater drug specificity, here's a review rdcu.be/eNiHj www.nature.com/articles/s41...

Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety www.nature.com/articles/s41... rdcu.be/eM8hs This new Perspective discusses QST models for multiple organs and provides recommendations for building and applying them

For readers interested in lipid nanoparticles for nucleic acid delivery, here's a perspective by Cullis and Feldner on the evolution of the field rdcu.be/eMpeO nature.com/articles/s41...

Trends in gene therapy delivery technologies nature.com/articles/d41... This article analyses trends in the delivery vehicles used for gene therapies in the clinical pipeline and discusses the potential characteristics of best-in-class delivery

Join researchers, biotech innovators, and pharma leaders in Boston this December for Cracking the Code: Nucleic Acid Medicines Coming of Age. Explore how advances in RNA and DNA therapeutics are shaping the next generation of medicine. go.nature.com/4nbCcaK 🧬#STEMconference

Intrinsically disordered proteins are frequently dysregulated in disease, but have traditionally been considered 'undruggable'. This Review in the October issue discusses experimental and computational approaches to conquer this barrier in drug discovery rdcu.be/eMbXh www.nature.com/articles/s41...

For readers interested in progress in the development of drugs for lupus, here's a comprehensive review rdcu.be/eL2Op www.nature.com/articles/s41...

BREAKING NEWS: The FDA has approved Gazyva® (obinutuzumab) for the treatment of adults with #lupus nephritis. Gazyva is the fourth therapy for lupus to receive regulatory approval since 2011. Read the announcement: buff.ly/81tYgo7

For readers interested in cancer therapies, this Review in the October issue discusses how metabolic modulators and dietary nutrients can improve the anticancer immune response and overcome drug resistance mechanisms rdcu.be/eLS8A www.nature.com/articles/s41...

Innovation in medicines for global health: a 20-year landscape analysis nature.com/articles/d41... This article analyses progress in the development of drugs for diseases including Ebola, trypanosomiasis, malaria, onchocerciasis, sickle cell disease, thalassaemia and tuberculosis

Cancer cachexia contender enters first pivotal trial www.nature.com/articles/d41... Can Pfizer’s appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help patients live longer in the process? Find out more in this news article #CancerGrandChallenges

#Cachexia is a common co-morbidity in a number of late stage cancers. It’s frequently seen in #PancreaticCancer. Most drug discovery companies are focused on treating the cancer itself, but late stage disease is often so biologically complex that this is a bit like banging your head against a wall.

Cancer cachexia contender enters first pivotal trial www.nature.com/articles/d41... Can Pfizer’s appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help patients live longer in the process? Find out more in this news article #CancerGrandChallenges

For readers interested in finding out more about in vivo CAR-T therapies such as those at the centre of the $1.5 billion acquisition of Orbital Therapeutics by Bristol Myers Squibb today, here's a comprehensive review rdcu.be/eKnwV nature.com/articles/s41...

Novo Nordisk's $4.7 billion upfront purchase of Akero to gain its FGF21 analogue for MASH today follows Roche's potential $3.5 billion deal around a similar drug from 89bio last month www.nature.com/articles/d41... Read more about FGF21 analogues in this review rdcu.be/eKbyo

Genmab nabs EGFR × LGR5 bispecific in US$8 billion Merus acquisition www.nature.com/articles/d41... For readers interested in bispecific antibodies in oncology, here's a comprehensive review rdcu.be/eJ2XM www.nature.com/articles/s41...

For readers interested in voltage-gated sodium channels as therapeutic targets, here's a comprehensive review nature.com/articles/s41... rdcu.be/eJSl0

Our latest research highlight covers a paper in Cell on the computational de novo design of a peptide modulator that addresses voltage-gated sodium channel dysfunction linked to epilepsy and cardiac arrhythmias nature.com/articles/d41...

Today's Nobel Prize for Physiology or Medicine relates to research on regulatory T cells www.nobelprize.org/prizes/medic... For readers interested in harnessing the biology of regulatory T cells to treat disease, here's a comprehensive review www.nature.com/articles/s41... rdcu.be/eJHU8

Targeting DNA damage in ageing: towards supercharging DNA repair www.nature.com/articles/s41... rdcu.be/eJIpr This Review in the October issue discusses approaches to pharmacologically mitigate adverse effects of DNA damage to delay ageing and prevent mutation-driven cancer

Our October issue is live! Read more about targeting protein disorder in drug discovery, metabolites as agents and targets for cancer immunotherapy, targeting DNA damage in ageing and more here www.nature.com/nrd/volumes/...

Review @natrevdrugdiscov.nature.com In vivo chimeric antigen receptor (#CAR)-T cell therapy www.nature.com/articles/s41...

In vivo CAR-T cell therapy www.nature.com/articles/s41... rdcu.be/eI7zH This new Review discusses how technological advances that remove the need for ex vivo manipulation and chemotherapeutic conditioning could enable wider application of CAR-T cell therapies in blood cancers and autoimmune diseases

This new article analyses the evolution of the pipeline and market for obesity drugs, which is being transformed by GLP-1-based therapies www.nature.com/articles/d41...

Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities www.nature.com/articles/s41... rdcu.be/eHOJ9 This new Review discusses progress with drugs targeting inflammatory cytokines such as IL-4 and IL-5, neutrophils, alarmins and kinases

Our latest research highlight covers two papers reporting novel NLRP3 inhibitors for inflammatory diseases www.nature.com/articles/d41... For readers interested in the NRLP3 inflammasome as a therapeutic target, here's a review www.nature.com/articles/s41... rdcu.be/eHePm

Join us for the 3rd Nature Conference on Nucleic Acid Medicines in Boston (Dec 8-10) with an amazing lineup of speakers. 4 weeks left 4 early bird registration! natureconferences.streamgo.live/cracking-the... @natureportfolio.nature.com @nature.com @natbiotech.nature.com @natrevdrugdiscov.nature.com

RNA modification systems as therapeutic targets www.nature.com/articles/s41... rdcu.be/eGTG8 This new Review discusses the disease roles of proteins that regulate RNA modification, and progress in targeting them, such as the RNA-methylating enzyme METTL3 in cancer

New US$3.1 billion foundation takes big, long-term bets on bioscience, AI and the environment www.nature.com/articles/d41... Lynda Stuart, president and CEO of the newly launched Fund for Science and Technology, discusses the philanthropic organization’s plans

Microsystem technologies for accelerating the discovery and translation of immunotherapies nature.com/articles/s41... rdcu.be/eGqYy This new review describes how microsystems can address efficacy, toxicity, predictability and affordability challenges with immunotherapies

Breakthrough therapy designations in China and the United States www.nature.com/articles/d41... This new article analyses breakthrough therapy programmes intended to help address unmet medical needs in the two countries

Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning www.nature.com/articles/d41...

New online: Synthetic lethality in cancer drug discovery: challenges and opportunities www.nature.com/articles/s41... rdcu.be/eFDCl This Review discusses advances in the discovery and validation of synthetic lethal pairs, and the development of drugs that target them

For readers interested in cancer therapies, this review discusses how metabolic dysfunction of CD8 T cells and NK cells can diminish their anticancer activity, and assesses therapeutic strategies to overcome this www.nature.com/articles/s41... rdcu.be/eFqm2

Chemical modification and engineering approaches for guide RNAs can enhance or enable CRISPR-based therapies by addressing issues such as delivery, stability, editing efficiency and off-target effects - find out more in this review www.nature.com/articles/s41... rdcu.be/eFb79

For readers interested in cancer therapies, this Review in our September issue discusses molecular pathways and effector functions by which neutrophils modulate cancer progression, and considers tractable therapeutic targets www.nature.com/articles/s41... rdcu.be/eEVmh

The gut microbiome has a key role in shaping the immune response to cancer and influencing the efficacy of immunotherapy. Read about advances in targeting the microbiome in cancer treatment in this Review in the September issue www.nature.com/articles/s41... rdcu.be/eD8M5

New approach methodologies offer the promise of greater predictivity of safety risks of drug candidates than animal models. Find out about progress in their application in drug development in this article in the September issue www.nature.com/articles/s41... rdcu.be/eDV1s

Therapeutic strategies aiming to enhance or inhibit regulatory T cell activity are being investigated in diseases including allergy, autoimmune disorders and cancer - find out more in this review by Megan Levings et al. www.nature.com/articles/s41... rdcu.be/eDrL0